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Abstract— Breast cancer is an important public health 
problem, with an estimated 3.2 million new cases by the 
year 2050. Diet plays a key role in the etiology of breast 
cancer and breastfeeding is associated with a lower 
incidence of breast cancer. On the other hand, the 
improvement of the therapeutic properties of bioactive 
compounds through their incorporation into 
microcarriers is an important strategy in obtaining new 
therapies, since cyclical changes in concentration are 
eliminated; there is biological availabil ity of the 
compound as well as the reduction in toxicity, number 
dose and suppression of adverse reactions. Studies using 
hormones such as melatonin extracted from human milk 
adsorbed onto polyethylene glycol (PEG) microspheres 
showed that the controlled release of this compound was 
able to reduce viability and induce apoptosis in MCF-7 
cell lines. Colostrum differs from most of the secretions 
because it contains viable leukocytes during the first days 
of lactation with a quantity and activity comparable to  
blood leukocytes, and has several defense components 
such as antibodies and hormones, such as melatonin 
(MLT). This review details the influence of the soluble 
and cellular components present in human colostrum, 
such as the MLT hormone, as the modified release 
systems influence the action of MLT and the possible 
mechanisms involved that contribute to the hypothesis of 
reduction of breast cancer in women who breastfed. 
Keywords— colostrum, melatonin, polyethylene glycol, 
breast cancer, bioengineering. 
 
I. INTRODUCTION 
Breast cancer cases have increased worldwide, and 
are directly related with more life expectancy, exposure to 
risk factors, and habits. Breast cancer is a multifactorial 
disease with a higher incidence among women, leading to 
death [1]. Cancer and chronic inflammation are closely 
linked and the imbalance between reactive oxygen species 
and antioxidant enzymes favors the emergence of these 
diseases. Thus the control of the production of reactive 
species as well as the maintenance of oxidative balance 
are primordial for the control of tumor progression [2, 3]. 
Some factors such as healthy lifestyle and 
breastfeeding are related to the prevention of breast 
cancer [4]. Human colostrum differs from other secretions 
by containing large quantities of viable leukocytes 
comparable to those found in blood acting as anti-
inflammatory mediators. It is believed that both soluble 
and cellular components interact with each other and may 
be important for antitumor immunity [5,6]. Breast milk is 
rich in soluble and cellular components, such as 
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phagocytes, secretory IgA immunoglobulin (SIgA), and 
hormones, especially melatonin (MLT) [5,7,8]. 
Melatonin, a hormone produced by the pineal 
gland, is involved in several physiological processes, 
including the functional regulation of breast milk. In milk 
it is related to the anti-inflammatory effects [9] and pro-
oxidant and antioxidant effects of paramount importance 
in the oxidative stress balance as a protection mechanism 
[10]. 
Some studies have reported that the bioavailability 
and biofunctional function of melatonin may be 
potentiated when associated in modified release systems 
[11,12]. Among these systems, polyethylene glycol 
(PEG) microspheres have been considered an important 
vehicle for the administration of various  drugs, natural 
products and hormones [13,14,15,16,17]. 
The administration of drugs adsorbed to carrier 
systems such as PEG microspheres has been an 
alternative treatment for various diseases [18], including 
breast cancer. These release systems are promising for the 
release of the hormone melatonin [11], preventing it from 
the degradation promoted by the metabolic enzymes 
increasing their bioavailability in the organism [19]. How 
much combined with the MLT has been demonstrated its 
ability to reduce cell viability and induce apoptosis in 
tumor cell lines from breast cancer [12,11]. 
The control of the process of carcinogenesis is 
closely related to the control of apoptosis, since the tumor 
cell is able to alter this system, favoring its proliferation 
and promotion [20]. Thus, cancer treatments are directed 
at inducing increased apoptosis of tumor cells [21, 22], 
which may be favored by the use of immunomodulatory 
agents such as MLT, for acting on immunocompetent 
cells and assisting in tumor eradication. 
This review details the influence of the soluble and 
cellular components present in human colostrum, such as 
the MLT hormone, and how they may be responsible for 
mechanisms that reinforce the hypothesis that 
breastfeeding reduces the risk of breast cancer. 
 
II. BREAST CANCER 
Breast cancer is a public health problem, with 
around 59,700 new cases in Brazil in the year 2018 [23]. 
The worldwide incidence and mortality of this disease are 
highly related and it is estimated that by the year 2050 
will appear about 3.2 million new cases of breast cancer 
in the world. Despite technological advances, there are 
still several mechanisms that must be elucidated in the 
eradication of this disease that affects the world 
population [24]. 
Breast cancer is considered a heterogeneous 
disease, both morphologically and clinically, and is due to 
a disordered proliferation of breast tissue cells. About 
80% of the types of breast tumors originate in the ductal 
epithelium, known as invasive ductal carcinoma [25]. 
Invasive carcinomas are so called because they have high 
metastatic potential, since carcinomas in situ have low 
metastatic potential and may arise in both lobes and 
mammary ducts [26]. During carcinogenesis, genetic 
mutations are accumulating and the cell phenotype is 
changing through malignant lesions, evolving into 
invasive cancer [27]. 
The structure of the breast is composed of 
glandular tissues composed of the milk producing glands 
and the ducts through which milk produced and stromal 
tissues pass, which are fibrous and fibrous  connective 
tissues. In addition to these tissues the breast is also 
composed of the tissue of the immune system and 
lymphatic system [28]. For normal development of breast 
tissue to occur, there is a need to balance cell proliferation 
and apoptosis. In tumor growth, there is a reduction in 
apoptosis and an increase in cell proliferation [27]. 
The balance between a protective cytotoxic 
response and a non-protective response can be regulated 
by the individual's overall immune status [29]. A major 
challenge for tumor research has been the identification of 
molecular and immunological changes associated with the 
different stages of tumor progression, and advances in 
these studies have been hampered by technical limitations 
to the pre-invasive stages of tumors [30]. 
The study with in vitro breast cancer cells began in 
1973 from isolated cells from pleural effusion of a 69-
year-old woman with metastatic disease [31]. MCF-7 
cells are useful for in vitro breast cancer studies by having 
several particular ideal characteristics of the mammary 
epithelium, such as the ability to process estrogen in the 
form of estradiol via estrogen receptors in the cell 
cytoplasm. This cell line is positive for the estrogen 
receptor (ER) and for the progesterone receptor and 
negative for HER2. These cells are very well studied with 
the immense number of protocols defined which allows 
researchers to use this cell line for study pathogenesis and 
in the search for treatment of breast cancer through 
reliable means in vitro assays [32]. During the last 
decade, several work on the mechanisms related to the 
interaction between the cells of the immune system and 
tumor progression. The results indicate that an immune 
response to a tumor is determined by the different cell 
types, such as lymphocytes, NK cells, neutrophils and 
others, as well as by the interactions between hormones, 
proteins and receptors present on the cell surface [33]. 
On the other hand, tumor cells arise from a mutation in 
DNA (deoxyribonucleic acid) that can be caused by 
radiation, bacteria, fungi, viruses, chemicals, etc. 
Although the components of the immune system are 
present and active, cancer cells can progressively grow 
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and spread, thus, the body weakened by poor diet, genetic 
predisposition, advanced age and exposure is the perfect 
environment for the development of cancer. In addition 
the cancer cells are very similar to the own cells of the 
organism, which hampers even more the response of the 
immune system [28]. 
Among the mutations, the most important alterations that 
occur are self-sufficiency in signs of proliferation, 
insensitivity to growth inhibitory signals, evasion of 
apoptosis, unlimited replicative potential, sustained 
angiogenesis and tissue invasion and metastasis [20]. 
The carcinogenesis process is directly involved with the 
generation of reactive oxygen species. Oxidative stress 
participates in all stages of cancer development. At 
initiation, oxidative species damage DNA by introducing 
genetic mutations and structural alterations; in the 
promotion, there is an increase of the initiated cell 
population, which is proliferation with consequent 
decrease of apoptosis; already in progression participate 
in the development of irreversible cancer growth [34]. 
 
III. BREASTFEEDING AND THE IMPORTANCE 
OF BREAST CANCER PREVENTION 
Breast cancer is the neoplasm most feared by 
women, since its occurrence causes great psychological, 
functional and social impact, acting negatively on issues 
related to self-image, social interaction and the perception 
of sexuality. It is considered of great importance in the 
health care of women, due to the high prevalence, 
morbidity and mortality [35]. 
The role of the immune system in cancer 
prevention is complex and partially understood. It is 
widely known that diet plays a fundamental role in the 
etiology of cancer [33] and that breastfeeding is 
associated with lower incidence of breast cancer. In this 
sense, studies have tried to elucidate the effects of 
lactation on breast cancer [36, 37]. There is evidence that 
human milk may confer long-term benefits and an 
increasing number of studies have indicated that 
breastfeeding provides protection against ovarian and 
breast cancer [38,39]. 
However, the effects of breastfeeding on the risk 
of breast cancer have been difficult to study because of 
the high correlation with parity [40, 41]. Reproductive 
factors may induce permanent changes in the epithelium 
of the mammary gland or in the surrounding stromal 
tissue [42,43]. Although the mechanisms have not been 
fully elucidated, the hypothesis of reducing the risk of 
breast cancer through breastfeeding seems to occur 
because of breast tissue differentiation or reduction in the 
number of ovulatory cycles [44]. 
Studies have revealed that the relative risk of 
having breast cancer reduces about 7,0% for each child 
born and about 4,3% for every 12 months of 
breastfeeding. This suggests that breastfeeding duration 
mothers is crucial to ensure the immunity components 
acts against the breast cancer [37,45] There is still 
evidence that breastfeeding protects women who have had 
their children under 50 years of age [46]. Another study 
reported that women who breastfed several children had 
the lowest risk of developing breast cancer, and mothers 
who breastfed four or more children had a 60 percent 
reduction in breast cancer risk. The magnitude of the 
protective effect is directly related to the time of 
breastfeeding [47]. 
Lactating mammary glands are an integral part of 
the mucosal immune system, and the antibodies and cells 
present in the milk reflect the antigenic stimulation of the 
Mucosa-Associated Lymphoid Tissue (MALT) in both 
the intestine and the respiratory tract. The literature 
reports that antibodies and human milk cells have 
specificity for a variety of antigens from intestinal and 
respiratory pathogens [48]. 
Colostrum differs from most of the secretions by 
containing viable leukocytes (109 cells / ml) during the 
first days of lactation [49], with amount and activity 
comparable to blood leukocytes [5]. On the other hand, 
other defense components present in the secretion that 
may be associated with protective activity, such as 
lactoferrin, analogous complexes (receptors), fatty acids 
(lipids), mucins [50], cytokines and chemokines [ 
51,52,53,54], antibodies such as IgA [55,56], lysozymes 
[52], probiotics [57], antioxidant factors [58], among 
other components produced by the maternal immune 
system, as well as several hormones such as to melatonin 
[59, 60, 15]. 
The concentrations of melatonin in human 
colostrum and mature milk  are similar the concentration 
of this hormone in the bloodstream. Also, 
immunocompetent colostrum cells can start to produce 
melatonin after stimuli from injuries, such as those caused 
by bacteria or fungal metabolites. Studies have shown that 
lymphocytes and peritoneal macrophages from rats  and 
human colostrum phagocytes produce melatonin in 
response to activation, and this production of melatonin in 
the site activates lymphocytes and macrophages to 
produce IL-12, IL-6, IFN-γ which increases the 
production of T lymphocytes, the presentation of antigens 
and the phagocytic activity of macrophages, thus 
increasing the local inflammatory aspect [61,62,63] and 
this synthesis of melatonin occurs by the same enzymatic 
pathway that occurs in human pinealocytes [64]. 
Immunocompetent breast cells remain highly 
permeable after childbirth, which makes this type of cell 
suitable for signaling pathways when collected in a non-
invasive manner, suggesting that these cells play an 
International Journal of Advanced Engineering Research and Science (IJAERS)                                [Vol-5, Issue-10, Oct- 2018] 
https://dx.doi.org/10.22161/ijaers.5.10.2                                                                                  ISSN: 2349-6495(P) | 2456-1908(O) 
www.ijaers.com                                                                                                                                                                              Page | 12  
important role in the protection of the newborn in 
pathological conditions these cells will be the defense of 
the newborn, thus consolidating the importance of 
breastfeeding [62]. 
 
IV. MELATONIN 
Melatonin is synthesized by the pineal gland 
[65]. It plays an important role in circadian rhythm 
control, reproduction, sleep-wake, is directly linked to the 
regulation of several neuroendocrine axes, protection 
against cancer and action against free radicals, acting on 
cell protection [66, 67]. Studies have shown that 
melatonin may increase the action of innate and acquired 
immunity and stimulate mainly leukocytes, an 
immunomodulatory property, which represents an 
important mechanism of protection for several diseases 
[9, 68, 8], as well as showing remarkable functional 
versatility oncotic properties, antioxidants and antiaging 
[69]. 
The action of direct melatonin against free 
radicals has been increasingly studied and its indirect role 
as an antioxidant has been tested and the effect has been 
highly effective in reducing oxidative stress in the body 
when compared to the antioxidants better known as 
vitamins C and E. Melatonin and its metabolites have 
positive aspects that make them effective in fighting free 
radicals. They easily cross the blood-brain and placental 
barrier, in addition to all maternal organs which leads to 
greater protection of the placenta and the fetus. Another 
positive aspect of melatonin is that it can be produced in 
other compartments, external to the pineal gland [66], and 
it has been speculated that all cells can synthesize 
melatonin, mainly in their mitochondria and this local 
production has the function of protection against radicals 
free [70]. 
The production of melatonin by other kinds of 
cells and organs has been reported, such as the retina, 
thymus, brain, intestine, bone marrow, ovary, testis, 
placenta, skin and lymphocytes [71]. High concentrations 
of melatonin have been found in skin keratinocytes, 
suggesting that the production of melatonin outside the 
pineal gland is not only related to the light / dark 
circadian rhythm, but rather as an antioxidant and anti-
inflammatory agent and as a mechanism of stress 
protection oxidative. This production of melatonin in 
response to oxidative stress occurs in all living beings, 
such as plants, unicellular beings, animals and man, and 
must have been the main function of melatonin in the 
primitive beings, since they did not have resources in the 
fight against free radicals. 
The production of melatonin by cells of the 
immune system occurs by activation of pro-inflammatory 
agents such as cytokines, increases the phagocytic 
capacity of macrophages and lymphocytes and induces 
the synthesis of interleukin-2 (IL-2), which has autocrine 
action and paracrine [69]. 
Melatonin acts on inflammatory processes and 
allergic diseases by attenuating the activation of NF-κB, 
reducing the production of TNF-α and IL-6 and 
promoting the survival of mast cells via a series of 
enzyme kinase activation and inhibition processes [72]. 
Melatonin exerts antioxidant action, which 
decreases the formation of free radicals, reducing the 
number of lesions that may affect cellular DNA [73]. It 
exerts an antiproliferative effect on physiological dose 
dependent breast cancer MCF-7 (human breast 
adenocarcinoma cell line) cells, in addition to reducing 
the rates of invasive and metastatic properties of this cell 
type [74]. Studies have shown that melatonin decreased 
cell proliferation and increased expression of p53 and p21 
proteins in MCF-7 cells, inhibiting proliferation and 
inducing apoptosis. The p53 protein is an important tumor 
suppressor gene and is involved in the regulation of the 
cell cycle [75]. Melatonin, via activation of the melatonin 
1 receptor (MT1) [76], is associated with suppression of 
growth and development of breast cancer through 
regulation of growth factors, regulation of gene 
expression, inhibition of tumor cell invasion and 
metastasis and by regulation of mammary gland 
development [77]. 
 
V. POLYETHYLENE GLYCOL (PEG) AND 
THERAPEUTIC APPLICATION IN 
BIOENGINEERING 
 Studies aimed at reducing adverse drug effects 
have been developed as novel therapeutic systems, known 
as modified release systems [78, 79, 80, 81, 82, 83]. The 
improvement of the therapeutic properties of bioactive 
compounds through their incorporation into microcarriers 
is an important strategy in obtaining new therapies, since 
cyclical changes in concentration are eliminated; there is 
biological availability of the compound as well as the 
reduction in toxicity, number of administered doses and 
suppression of adverse reactions [84]. 
PEG-drug conjugates and microemulsions -drug, 
are being studied as possible modified release systems for 
a variety of molecules and drugs [85, 86, 87, 88, 89, 90, 
91, 92, 83]. This combination has many advantages such 
as prolonged residence in the organism, decreased 
degradation by metabolic enzymes and reduction or 
elimination of the immunogenicity of proteins [87]. 
 Several studies have shown that the association of 
PEG microspheres with molecules, hormones or proteins 
increases the immunomodulatory capacity of both blood 
and colostrum phagocytes and suggests  that the 
adsorption of these compounds to PEG microspheres has 
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immunostimulatory effects and can be considered a 
important material/vehicle, with potential for future 
therapeutic applications in infectious diseases or tumors 
[13, 15, 14, 17, 16, 93]. 
Studies using hormones such as melatonin and 
secretory IgA antibodies extracted from human milk 
adsorbed onto PEG microspheres showed that the 
controlled release of this compound was able to reduce 
viability and induce apoptosis in MCF-7 cell lines 
[11,12]. Other herbicidal and barium chloride studies, 
adsorbed to PEG microspheres on human blood 
mononuclear cells co-cultured with breast cancer cell 
lines (MCF-7), showed a pro-apoptotic effect in breast 
cancer cells MCF-7 human [94, 95]. Immunotherapy for 
tumor treatments based on cytotoxic properties of 
immunocompetent cells has also been the focus of many 
studies. Both T cells and phagocytic cells are considered 
effectors with antitumor activity [96]. The melatonin 
adsorbed to the PEG microsphere was able to increase the 
functional activity of colostrum phagocytes and that this 
modified hormone release system may represent an 
alternative in the treatment of diseases  [17].  
 Here we hypothesize that melatonin adsorbed on 
PEG microsphere may be effective in the treatment of 
breast cancer. The possible interactions between 
components present in human milk and therapy of 
bioengineered melatonin as a strategy for the prevention 
and treatment of breast cancer are shown in figure 1. 
 
Fig.1: Hypothetical model of therapy with Melatonin 
bioengineered 
Additionally the chronotherapy, the practice of 
drug administration according to the circadian rhythm, is 
intended to maximize efficacy and minimize toxicity in 
the body. This approach has proven advantageous in 
several diseases, such as cancer and asthma [97] and has 
been an alternative of treatments based on melatonin. 
On the other hand, the expected response by 
chemotherapy, radiotherapy, hormone treatments, is the 
induction of apoptosis, since the balance between cell 
proliferation and apoptosis is determinant for its growth 
[98]. After initiation of chemotherapy, within 24 h there is 
a significant increase in apoptosis in breast tumors, 
associated with decreased proliferation. This response 
may occur differently in the various tumor types, and at 
the end of the chemotherapies there is an increase in the 
levels of the anti-apoptotic Bcl-2 protein, which favors 
the occurrence of chemoresistant residual cells, which 
may be important for tumor recurrences [99]. ]. 
The anti-apoptotic role in normal and pro-
apoptotic cells in cancer cells has been reported in studies 
with melatonin, giving prominence to this hormone, since 
conventional cancer treatments can not do this 
discrimination between healthy cells and cancer cells, 
placing it in a prominent position in the search for 
effective treatment against various types of cancer, and 
especially against breast cancer [100]. 
 
VI. CONCLUSION 
Major advances in cancer therapy have been 
occurring, and the study of the use of melatonin in cell 
culture or in vivo oncology has shown promise. The 
mechanisms of action of melatonin in reducing oxidative 
stress and the activation of apoptosis in cancer cells has 
put this hormone as a highlight in the adjuvant use of 
cancer treatment. 
 And considering that the breast tissue is in 
constant and direct contact with the soluble and cellular 
immune components in the milk, and the numerous 
immunological constituents of the breast milk, among 
these high concentrations of melatonin, macrophages, it is 
possible that interactions of these components, directly or 
modified release systems with factors present in tumor 
cells may be an alternative for tumor immunotherapy. 
 There is still much to study and develop to 
further increase the cure rates of cancer patients, as well 
as eradicate the occurrence of adverse reactions that both 
discomfort and incapacitate the patient, often leading to 
withdrawal of treatment. There is a need to improve the 
studies around melatonin as an immunomodulatory agent 
of colostrum phagocytes in the action against breast 
cancer cells, since these cells are present in large 
quantities, mainly in women who have breastfed, which 
can increase even more the chances of prevention against 
breast cancer. 
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